Minnesota Senate Finance Committee
May, 2013

The Decade of Discovery (DoDD) was
• Text
University of Minnesota to conquer a disease with devastating physical, economic and social impacts: diabetes.
Decade of Discovery aligns and integrates the significant resources and strengths of Mayo Clinic and the University through a disciplined, goaldirected approach to prevent, optimally treat and ultimately cure Type 1 and Type 2 diabetes.
2

Management Team
David D. Etzwiler, J.D., M.P.P. – Executive
Director
Former Vice President of Community Affairs and
Executive Director of the Medtronic Foundation
Maura Donovan, Ph.D. – Chief Technology
Officer
Former Vice President, Therapy R&D for
Medtronic Corporate Ventures and New
Therapies
Oversight Committee
Kathleen Blatz, M.S., J.D. — Co-chair; former Chief
Justice of the Minnesota Supreme Court
Vance Opperman, J.D. — Co-chair; Key Investment,
Inc., MSP Communications
Ann Albright, Ph.D., R.D. — Centers for Disease
Control and Prevention
Richard M. Bergenstal, M.D. —International
Diabetes Center, American Diabetes Association
(former President)
Jackie Casey —Juvenile Diabetes Research
Foundation International (JDRF), Minnesota Chapter
Frank B. Cerra, M.D. — University of MN
Elizabeth Seaquist, M.D. – Program Lead
President-Elect, American Diabetes Association, professor, Department of Medicine in Division of
Endocrinology and Diabetes at the University of MN
Steven Smith, M.D. – Program Lead
Medical Director for Patient Education, Mayo
Clinic, past Chair of Diabetes Core Group: Division of Endocrinology, Diabetes, Nutrition, and
Metabolism
Susan Crockett, Ph.D. — General Mills
Michael Gorman, M.B.A, J.D. — Split Rock Partners
Chris Schaeffer — American Diabetes Association,
Minnesota Chapter
Eric J. Jolly, Ph.D. — Science Museum of Minnesota
David M. Kendall, M.D. — Eli Lilly
Cindy Kent — Medtronic, Inc.
Dale Wahlstrom, M.S. — LifeScience Alley and the
BioBusiness Alliance of Minnesota

• More than 25 million Americans have diabetes; 79 million have prediabetes
• • Text
DIABETES COSTS
• $3.1 billion annually in MN
• Estimated to grow to $6.4 billion by 2025
• $200 billion in 2010 in U.S.
• Estimated to be more than $500
billion in 2020
IN MINNESOTA
- Diabetes doubled among adults since
1995
- 290,000 adults with diabetes in MN
- 1.4 million adults with prediabetes
- Every year 20,000 Minnesotans diagnosed
- 6th leading cause of death
- Risk of heart disease and stroke is 2-4 times higher than for those without
- Leading complication among mothers giving birth
4

• Text
Research
Strong , goal-directed research with a focus on “fast translation” to a cure, employing team science that incorporates the best of academia and industry working together toward a common, transformative goal
A “mission-driven” commitment to large-scale care delivery and prevention work with an understanding of system needs and the required alliances to impact those needs
Community
Prevention
Governance
Rigorous governance and program management across scientific and clinical themes with clearly defined milestones and metrics
5

Drug discovery: identify targets for intervention based on key metabolic and autoimmune processes and physiological mechanisms that underpin type 1 and type 2 diabetes
Cell-biology based therapies: replace/sustain beta cell function through regeneration, reprogramming and replacement including beta cell biology, regenerative medicine, gene therapy, and transplantation
Devices: accelerate technologies by combining biological, mathematical and engineering knowledge to develop novel ways to treat and deliver cures for diabetes
Rigorous RFP Process to Identify Lead Programs
6

Preclinical
(in vivo / animal studies) Discovery
Phase 1
(1 st human dose to 1 st patient dose)
Phase 2
(1 st patient dose to 1 st pivotal dose)
Phase 3
(1 st pivotal dose to reg. submission)
Regulatory
Submission
Probability of a substance moving to the next phase: varies varies ~55% ~25% ~70% ~95%
Approval
Many ideas will be brought into the program to increase the chance of success
Project plans will include go-no go criteria and well defined milestones
Progress against milestones will be regularly assessed
7

#1 in Diabetes
&
Endocrinology
(2012 report)
Industry and academic partnering is a priority
Industry is looking for innovation
• # of diabetes patents is decreasing while incidence is escalating
• Historically, a majority of the novel pharmaceuticals comes from academia and biotech
Different partnering models are being pursued
All eyes will be on MN as a catalyst for innovation in diabetes therapy development
8

Decade co-leads statewide coalition with mission to become the state with the lowest incidence and the healthiest outcomes for diabetes in the nation.
• Prevention Strategy
• Identify, prioritize and scale evidence based interventions with the highest benefit for participants and public/private payers
• National Diabetes Prevention Program
• MN poised to be first state in the U.S. to implement NDPP on large scale
American Diabetes Association
Courage Center
Collective Impact Participants include:
BCBS of Minnesota
Decade of Discovery
Centers for Disease Control & Prevention
Essentia Health
Governor’s Task Force/Health Care HealthEast
ICSI
HealthPartners
International Diabetes Center The Isuroon Project
LifeScience Alley
MN Community Measurement
Minneapolis Urban League
Mayo Clinic Health System Medica
MN Department of Health MN Health Action Group
Novo Nordisk Sanford Health System
SEIU Healthcare Minnesota
Southside Community Clinic
United Way
YMCA of the Greater Twin Cities
Stairstep Foundation
Ucare
University of Minnesota
Stratis Health
UnitedHealth Group
West Side Community Health
9

Through the Decade of Discovery,
Minnesota has the opportunity to play a
• Text
 Improve public health by transforming the lives of people with diabetes
 Deliver multi-billion dollar savings to the health care system, to employers, government payers and families by reigning in the huge and growing costs associated with diabetes
 Stimulate significant economic development – creating new businesses and jobs from our research
10